Abstract 20722: The Insulin-Like Growth Factor Binding Protein 5 (IGFBP5) - A Potential Biomarker for Heart Failure Transition

Introduction: Available pharmacological treatments for cardiovascular diseases (CVD) delay, but do not prevent the onset of heart failure (HF). To succeed with novel interventions preventing HF, it is essential to identify stage-specific mechanisms involved in the transition to maladaptive heart remodeling. Insulin-like growth factor binding proteins (IGFBPs) are increasingly recognized factors in understanding the pathogenesis and severity of CVD. Hypothesis: IGFBP5 is a novel cardiac- and disease stage-specific biomarker reporting heart failure progression. Results: Igfbp5 mRNA expression is high in early cardiac mesoderm (stage E9.5); becoming markedly decreased in the adult heart (E9.5 / adult; 0.82 ± 0.015, n=3 / 0.05 ± 0.003, n=3) and is significantly elevated in the adult heart upon transvers aortic constriction (TAC) during the transition to HF (TAC / Sham; 2.18 ± 0.23, n=8 / 1.4 ± 0.15, n=6). This upregulation was prevented in a mouse model with cardiomyocyte specific β-catenin loss of function, ...